Oesophageal Adenocarcinoma research hub

Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery

This study looks at oesophageal and stomach cancer patients after surgery. We're collecting samples over time to find early signs (biomarkers) that can predict how well treatments work, if the cancer might come back, or long-term health outcomes. The goal is to improve understanding and care for these cancers.

A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

This study, called ASPEN-06, looked into an experimental drug called Evorpacept for people in the UK with advanced stomach cancer (gastric cancer) that has a specific genetic marker (HER2-positive). It aimed to see if adding Evorpacept to standard treatments improved outcomes. The study has now been stopped due to strategic reasons.